The U.S. Food and Drug Administration approved Mylan NV's Ogivri, a biosimilar to Roche Holding AG's Herceptin, for the treatment of patients with certain types of breast and stomach cancer. The federal agency said it is the first biosimilar approved ...
The FDA Ushers In a New Era in Cancer Treatment
On Thursday, Foundation Medicine (NASDAQ:FMI) won a green light for its comprehensive DNA test, FoundationOne CDx. The approval clears the way for healthcare providers to quickly determine what cancer therapies may work best based on next-generation ...
No comments:
Post a Comment